Clinical trials: IDIOPATHIC PARKINSON'S DISEASE
- Condition IDIOPATHIC PARKINSON'S DISEASE
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Parkinson's Disease, Idiopathic
A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
The purpose of this study is to measure safety and efficacy of buntanetap/posiphen capsules compared with placebo capsules in participants with early PD. Study details include: The study duration will be up to 7-8 months.
- Trial name
- NCT05357989
- Testing
- buntanetap/posiphen
- Where
- 69 sites in United States, Germany and 4 more
- Volunteers
- 523 people
- Sponsor
- Annovis Bio Inc.
Parkinson Disease, Idiopathic Parkinson Disease
An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)
The primary purpose of this extension study is to assess the long-term safety and tolerability of preladenant in participants from parent studies NCT01155466 [P04938] and NCT01227265 [P07037] with moderate to severe Parkinson's…
- Trial name
- NCT01215227
- Testing
- Preladenant, Rasagiline
- Volunteers
- 839 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.
Parkinson's disease (PD) is a neurodegenerative disorder of unknown aetiology with an estimated incidence of 4.5-16/100,000 persons/year.
- Trial name
- BIPARKII (NCT01227655)
- Testing
- BIA 9-1067, Levodopa, Carbidopa
- Where
- Portugal
- Volunteers
- 427 people
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease
This is primarily a safety protocol to evaluate the safety of subthalamotomy using Transcranial ExAblate for treatment of Parkinson's Disease (PD) motor features.
- Trial name
- NCT02246374
- Testing
- ExAblate Transcranial System
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- InSightec
Idiopathic Parkinson Disease
Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
This is a Phase IV, prospective, observational, post-marketing study designed to obtain additional data on the effect of XADAGO on motor and non-motor symptoms in Parkinson's Disease patients newly prescribed XADAGO.
- Trial name
- PRO-Go (NCT03944785)
- Testing
- XADAGO (safinamide)
- Where
- 30 sites in United States
- Volunteers
- 164 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Idiopathic Parkinson's Disease
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
The purpose of this study was to evaluate the safety and potential benefits of CERE-120 in the treatment of Parkinson's disease.
- Trial name
- NCT00985517
- Testing
- CERE-120: Adeno-Associated Virus Delivery of Neurturin
- Where
- 11 sites in United States
- Volunteers
- 57 people
- Sponsor
- Sangamo Therapeutics
Parkinson's Disease (Disorder)
A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations
To evaluate the safety and efficacy of IPX203 (carbidopa and levodopa) extended-release capsules (IPX203 ER CD-LD) in comparison to immediate release (IR) CD-LD in the treatment of CD-LD-experienced participants with Parkinson's…
- Trial name
- NCT03670953
- Testing
- IR CD-LD, IPX203 ER CD-LD
- Where
- 108 sites in United States, Czechia and 6 more
- Volunteers
- 630 people
- Sponsor
- Impax Laboratories, LLC
Early-Stage Parkinson's Disease
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease.
- Trial name
- SP512OL (NCT00594165)
- Testing
- Rotigotine
- Where
- 42 sites in United States, Canada
- Volunteers
- 217 people
- Sponsor
- UCB Pharma
Early Stage Parkinson's Disease
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease
- Trial name
- NCT00599196
- Testing
- Rotigotine
- Where
- 63 sites in Australia, Austria and 18 more
- Volunteers
- 381 people
- Sponsor
- UCB Pharma
Idiopathic Parkinson Disease
Effect of Safinamide on Parkinson's Disease Related Chronic Pain
Primary objective: To evaluate the potential efficacy of safinamide 100 mg once daily (OD), compared with placebo, as add-on therapy for PD-related chronic pain Secondary objectives: Percentage of pain responders Clinical Global…
- Trial name
- NCT03841604
- Testing
- Safinamide Methanesulfonate
- Where
- 45 sites in Austria, France and 3 more
- Volunteers
- 94 people
- Sponsor
- Zambon SpA
Idiopathic Parkinson's Disease
Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy
This trial is being conducted to assess the effects of Rotigotine over Placebo on improvement of Apathy and motor symptoms in subjects with early-stage and advanced stage idiopathic Parkinson´s Disease.
- Trial name
- BRIGHT (NCT01782222)
- Testing
- Rotigotine
- Where
- 42 sites in United States, Austria and 5 more
- Volunteers
- 122 people
- Sponsor
- UCB BIOSCIENCES GmbH
Idiopathic Parkinson's Disease
Randomized Safety Study of CVT-301 Compared to an Observational Control Group
This study is a 12-month, open-label, randomized, multicenter study which will evaluate the safety and efficacy of CVT-301 for the treatment of up to 5 OFF episodes per day in Parkinson's Disease (PD) patients experiencing motor…
- Trial name
- NCT02352363
- Testing
- CVT-301, Observational cohort
- Where
- 76 sites in United States, Austria and 12 more
- Volunteers
- 408 people
- Sponsor
- Acorda Therapeutics
Idiopathic Parkinson's Disease
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
This is a study to assess the efficacy and safety of oral Istradefylline (KW-6002) in patients with moderate to severe Parkinson's Disease.
- Trial name
- KW-6002 (NCT01968031)
- Testing
- Istradefylline 40 mg, Istradefylline 20 mg
- Where
- 89 sites in United States, Canada and 6 more
- Volunteers
- 613 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Idiopathic Parkinson Disease
Transdermal Rotigotine User Surveillance Study
This study will be conducted in an observational multiple-cohort design aimed at acquiring clinical, treatment, health status, and economic data. Patients with Parkinson's disease (PD) will be enrolled.
- Trial name
- TRUST (NCT00599339)
- Where
- 211 sites in Czechia, Denmark and 8 more
- Volunteers
- 2,195 people
- Sponsor
- UCB Pharma
Parkinson's Disease
Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease
The objective of this open-label extension is to assess the long-term effect of the 24-hour transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal and non-motor symptoms of Parkinson's disease.
- Trial name
- NCT00519532
- Testing
- Rotigotine
- Where
- 21 sites in United States, Australia and 9 more
- Volunteers
- 84 people
- Sponsor
- UCB Pharma
IDIOPATHIC PARKINSON'S DISEASE
Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients
The primary objective is to demonstrate that the Rotigotine transdermal patch is efficacious in Chinese subjects with early-stage idiopathic Parkinson's disease.
- Trial name
- NCT01646268
- Testing
- Rotigotine
- Where
- 24 sites in China
- Volunteers
- 249 people
- Sponsor
- UCB Pharma
Parkinson's Disease
Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease
The purpose of this trial is to assess whether rotigotine has an effect on the electrical activity of the heart. Moxifloxacin infusion is used as positive control to assess assay sensitivity.
- Trial name
- NCT00292227
- Testing
- Rotigotine, Moxifloxacin infusion
- Where
- 2 sites in South Africa
- Volunteers
- 130 people
- Sponsor
- UCB Pharma
Idiopathic Parkinson's Disease
Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients
Phase 3, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 3-arm safety and efficacy study (Part A) with an open-label phase (Part B).
- Trial name
- TOZ-PD (NCT02453386)
- Testing
- tozadenant
- Where
- 71 sites in United States, Austria and 5 more
- Volunteers
- 449 people
- Sponsor
- Biotie Therapies Inc.
Idiopathic Parkinson's Disease
Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
This study is a 12-month, dose-level blinded, multicenter study of 2 inhaled dose levels of CVT-301 for the treatment of up to 5 OFF episodes per day in PD patients experiencing motor fluctuations (OFF episodes).
- Trial name
- NCT02242487
- Testing
- CVT-301
- Where
- 74 sites in United States, Canada and 3 more
- Volunteers
- 325 people
- Sponsor
- Acorda Therapeutics
Parkinson Disease
A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)
When a patient with Parkinson's disease (PD) is initially treated with L-dopa or dopamine agonists, the symptoms of PD improve or disappear.
- Trial name
- NCT01155466
- Testing
- Preladenant 2 mg tablet, Preladenant 5 mg tablet, Preladenant 10 mg tablet
- Volunteers
- 778 people
- Sponsor
- Merck Sharp & Dohme LLC